由于急性不补偿性心力衰竭,在心脏性休克中使用米利诺改善了死亡率和血液动力学
Eduard Rodenas-Alesina1,2, Fernando Luis Scolari1,2, Vicki N Wang1,2
1Ted Rogers Centre for Heart Research, Peter Munk Cardiac Centre, University Health Network, Toronto, Ontario, Canada.
ESC heart failure
|June 16, 2023
概括
与多布胺相比,在与心脏性休克 (ADHF-CS) 相关的急性不补偿性心力衰竭中使用米利诺的30天死亡率较低. 这种内扩散剂疗法改善了这些重症患者的血液动力学参数.
科学领域:
- 心脏病学 心脏病学
- 关键护理医学 关键护理医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 心脏性休克 (CS) 患者群体通常是异质的,包括急性心肌梗塞和急性不补偿性心力衰竭 (ADHF-CS) 患者.
- 米利诺的治疗特征可能会在ADHF-CS中带来好处.
- 在ADHF-CS中,milrinone和dobutamine之间的比较结果数据有限.
研究的目的:
- 为了比较ADHF-CS患者的结局和血液动力学趋势,他们接受了milrinone或dobutamine治疗.
- 评估米利诺与多布胺对ADHF-CS.30天死亡率的影响.
- 在这个患者队列中,与多布他胺相比,评估milrinone的血液动力学影响.
主要方法:
- 在2014年至2020年期间,对573名ADHF-CS患者进行了回顾性研究,这些患者接受了米利诺或多布胺治疗.
- 收集的数据包括临床特征,结果和血液动力学参数.
- 主要终点是30天死亡率,根据基线特征和倾向匹配进行调整.
主要成果:
- 接收米利诺的患者年轻,功能较好,乳酸盐水平较低.
- 米利诺尼使用与明显较低的调整后30天死亡率相关 (HR=0.52),并且在倾向匹配后仍然显著 (HR=0.51).
- 米利诺尼治疗与改善的肺动脉顺应,中风量和右心室中风工作指数相关.
结论:
- 与dobutamine相比,在ADHF-CS中使用milrinone与30天死亡率的降低有关.
- 在ADHF-CS患者中,米利诺显示出有利的血液动力学改善.
- 通过随机对照试验进行进一步的调查是有必要的,以证实这些发现.
更多相关视频
14:35Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
8.6K
08:01Semi-Minimal Invasive Method to Induce Myocardial Infarction in Rats and the Assessment of Cardiac Function by an Isolated Working Heart System
Published on: June 11, 2020
8.2K
相关概念视频
01:30Heart Failure V: Medical Management
16
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
16
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
469
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
469
01:30Cardiomyopathy II: Dilated Cardiomyopathy
12
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
12
01:26Heart Failure Drugs: Inotropic Agents
641
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
641
01:22Mitral Stenosis I: Introduction
18
Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
18
01:29Cardiomyopathy V: Interprofessional Care
18
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
18